公开(公告)号：EP2868743A2

公开(公告)日：2015-05-06

申请号：EP15152934.4

申请日：2007-09-28

Applicant: LOMA LINDA UNIVERSITY

Inventor： Li, Fengchun ,  Escher, Alan P.

IPC: C12N5/071 ,  C12N15/113 ,  A61K31/7088

CPC classification number: C12N5/0602 ,  A61K31/7088 ,  A61K35/12 ,  A61K39/001 ,  A61K2035/122 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/531

Abstract: Mammalian host cells for use in a cell-mediated transfection process, which contain an RNAi molecule and an expression vector for a pro-apoptotic protein. The method includes inducing apoptotic cell (AC) death in mammalian cells that contain an RNAi molecule capable of down-regulating a chosen target gene. Living cells expressing the target gene are then exposed to the ACs. The ACs are processed by the living cells, and the RNAi molecule in the ACs down-regulates the expression of the target gene in living cells.

Abstract translation: 用于细胞介导的转染过程的哺乳动物宿主细胞，其含有RNAi分子和促凋亡蛋白的表达载体。 该方法包括在含有能够下调选择的靶基因的RNAi分子的哺乳动物细胞中诱导凋亡细胞（AC）死亡。 然后将表达靶基因的活细胞暴露于AC。 AC由活细胞处理，ACs中的RNAi分子下调细胞中靶基因的表达。

公开(公告)号：EP2090317B1

公开(公告)日：2010-10-13

申请号：EP09003866.2

申请日：2001-04-17

Applicant: LOMA LINDA UNIVERSITY

Inventor： Escher, Alan P. ,  Liu, Jingxue

IPC: A61K38/43

CPC classification number: A61K31/70 ,  A61K38/44 ,  A61K38/51 ,  A61K48/00 ,  C12Y113/12005 ,  C12Y401/01015

公开(公告)号：EP2090317A1

公开(公告)日：2009-08-19

申请号：EP09003866.2

申请日：2001-04-17

Applicant: LOMA LINDA UNIVERSITY

Inventor： Escher, Alan P. ,  Liu, Jingxue

IPC: A61K39/00 ,  C12N15/11 ,  A61K48/00

CPC classification number: A61K31/70 ,  A61K38/44 ,  A61K38/51 ,  A61K48/00 ,  C12Y113/12005 ,  C12Y401/01015

Abstract: A method for preventing, delaying the onset of or treating diabetes in a patient comprising selecting a patient who is susceptible to developing diabetes, who is developing diabetes or who is diabetic and administering to the patienet one or more than one dose of a pharmaceutical agent comprising a polynucleotide encoding a secreted exogenous protein, namely luciferase.

Abstract translation: 一种用于预防，延缓患者糖尿病发作或治疗患者的方法，包括选择易患发展中的糖尿病患者，正在开发糖尿病或糖尿病患者，并向患者施用一种或多于一种剂型的药剂，其包含 编码分泌的外源蛋白质的多核苷酸，即荧光素酶。

公开(公告)号：EP1624053A1

公开(公告)日：2006-02-08

申请号：EP05021001.2

申请日：2003-08-06

Applicant: LOMA LINDA UNIVERSITY

Inventor： Escher, Alan P. ,  Li, Fengchun

IPC: C12N5/00 ,  C12N15/00 ,  C12N15/87 ,  A61K48/00

CPC classification number: A61K48/00 ,  A61K38/1709 ,  A61K39/0008 ,  A61K48/005 ,  A61K2039/53 ,  A61K2039/55516 ,  C07K14/005 ,  C07K14/4713 ,  C07K14/4747 ,  C12N5/00 ,  C12N15/00 ,  C12N15/87 ,  C12N2710/10322 ,  C12N2840/203

Abstract: A substance is disclosed for preventing, delaying the onset of or treating one or more than one autoimmune disease, the substance comprising a combination of a polynucleotide construct comprising a polynucleotide sequence encoding ΔBCL-2 and encoding one or more than one autoantigen for the autoimmune disease. A use is also disclosed of a polynucleotide construct comprising a combination of a polynucleotide construct comprising a polynucleotide sequence encoding ΔBCL-2 and encoding one or more than one autoantigen for the autoimmune disease, for the manufacture of a medicament for preventing, delaying the onset of or treating one or more than one autoimmune disease.

Abstract translation: 公开了用于预防，延迟一种或多种自身免疫性疾病的发作或治疗一种或多种自身免疫性疾病的物质，所述物质包含多核苷酸构建体的组合，所述多核苷酸构建体包含编码ΔBCL-2的多核苷酸序列并编码自身免疫性疾病的一种或多种自体抗原 。 还公开了包含含有编码ΔBCL-2的多核苷酸序列并编码一种或多种自身免疫性疾病的自身抗原的多核苷酸构建体的组合的多核苷酸构建体在制备用于预防，延缓 或治疗一种或多种自身免疫性疾病。